Shilpa Pharma Lifesciences Limited has received a CEP from EDQM for its API, Teriflunomide, which is used in treating multiple sclerosis and is effective with oral administration. This is the 25th CEP issued to Shilpa by EDQM, highlighting its commitment to quality products.